Clindamycinhydrochlorid

Bezeichnung:Clindamycinhydrochlorid

CAS-Nr21462-39-5

Englisch Name:Clindamycin hydrochloride

CBNumberCB2398837

SummenformelC18H34Cl2N2O5S

Molgewicht461.44

MOL-Datei21462-39-5.mol

Synonyma

Clindamycinhydrochlorid

Clindamycinhydrochlorid physikalisch-chemischer Eigenschaften

Schmelzpunkt	141°C
storage temp.	2-8°C
Löslichkeit	H₂O: 50 mg/mL, clear, colorless
Farbe	White to Off-White
BRN	4070786
Stabilität	Hygroscopic
InChIKey	AUODDLQVRAJAJM-XJQDNNTCSA-N
SMILES	[C@@H]1([C@@H]([C@H](C)Cl)NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](O)[C@H](O)[C@H]([C@@H](SC)O1)O.Cl \|&1:0,1,2,8,10,17,19,21,22,r\|
CAS Datenbank	21462-39-5(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher	Xi
R-Sätze:	36/37/38
S-Sätze:	26-36-37/39
WGK Germany	2
RTECS-Nr.	GF2275000
F	10
HS Code	29419000

Gefahreninformationscode (GHS)

Clindamycin hydrochloride Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:
R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.
S-Sätze Betriebsanweisung:
S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.
S37/39:Bei der Arbeit geeignete Schutzhandschuhe und Schutzbrille/Gesichtsschutz tragen.
Chemische Eigenschaften
White Solid
Originator
Dalacin-C,Diethelm,Switz.,1968
Verwenden
Labelled Clindamycin. Semi-synthetic antibiotic prepared from Lincomycin;Labeled Clindamycin, intended for use as an internal standard for the quantification of Clindamycin by GC- or LC-mass spectrometry.
Verwenden
antibacterial, inhibits protein synthesis
Verwenden
Clindamycin hydrochloride is a salt of clindamycin, a semi-synthetic lincosamide. The hydrochloride salt forms at the basic N-ethylproline moiety and is the preferred pharmaceutical formulation. Like other members of the lincosamide family, clindamycin is a broad spectrum antibiotic with activity against anaerobic bacteria and protozoans. Clindamycin hydrochloride acts by binding to the 23S ribosomal subunit, blocking protein synthesis. Clindamycin hydrochloride has been extensively studied with over 8,000 literature citations.
Definition
ChEBI: Clindamycin hydrochloride is a S-glycosyl compound.
Manufacturing Process
The following procedure is described in US Patent 3,475,407. A solution of 50 g of lincomycin hydrochloride, 120 g of triphenylphosphine, and 500 ml of acetonitrile in a 3 liter flask equipped with a stirrer was cooled in an ice bath and 500 ml of carbon tetrachloride was added in one portion. The reaction mixture was then stirred for 18 hours without addition of ice to the cooling
bath. The reaction was evaporated to dryness under vacuum on a 50° to 60°C water bath, yielding a clear, pale yellow viscous oil. An equal volume of water was added and the mixture shaken until all of the oil was dissolved. The resulting suspension of white solid (Ph3PO) was filtered through a sintered glass mat and discarded. The filtrate was adjusted to pH 11 by addition of 6 N aqueous sodium hydroxide. A solid precipitated.
The resulting slurry was extracted with four 300 ml portions of chloroform. The aqueous phase was discarded. The combined chloroform extract was washed once with 100 ml of saturated aqueous sodium chloride solution and the sodium chloride phase was discarded. The chloroform phase was evaporated to dryness under vacuum on a 50° to 60°C water bath and an equal volume of methanol was added to the residue and the resulting solution heated at reflux for 1 hour. The methanol solution was evaporated to dryness under vacuum on a 50° to 60°C water bath. The residue was a clear pale yellow viscous oil. An equal volume of water and 10 ml of 37% aqueous HCl was added and the resultant was shaken until the oil dissolved and a white solid (more Ph3PO) remained in suspension. The suspension was filtered through a sintered glass mat at pH 1 to 2 and the solid discarded.
The filtrate was extracted twice with 100 ml of carbon tetrachloride. The carbon tetrachloride phase was discarded. The aqueous phase was adjusted to pH 11 by addition of 6 N aqueous sodium hydroxide and extracted four times with 300 ml portions of chloroform. The combined chloroform extract was washed three times with 100 ml of saturated aqueous sodium chloride solution and the sodium chloride phase was discarded. The chloroform extract was dried over anhydrous magnesium sulfate, filtered and the filtrate evaporated to dryness under vacuum on a 50° to 60 °C water bath. The residue was a clear, colorless glass weighing 45 g analyzing about 95% 7(S)- chloro-7-deoxylincomycin. To the crude product there was added 100 ml of ethanol with warming until a clear solution was obtained. Then 150 ml ethyl acetate was added and the resultant filtered through a glass mat and the filtrate adjusted to pH 1 by the addition of saturated ethanolic HCl. Crystallization soon occurred. The resultant was allowed to stand at 0°C for 18 hours and then filtered through a sintered glass mat. The solid was dried under vacuum at 60°C for 18 hours yielding 35 g, a 67% yield of 7(S)-chloro- 7-deoxylincomycin hydrochloride as an ethanol solvate.
Trademarks
Cleocin (Pharmacia & Upjohn).
Therapeutic Function
Antibacterial
Allgemeine Beschreibung
Chemical structure: macrolide
Kontakt-Allergie
This lincosanide antibiotic is used in topical form for acne, or systemically has been responsible for exanthematous rashes and acute generalized exanthematous pustulosis.
Biochem/physiol Actions
Clindamycin hydrochloride is highly effective against anaerobic species.
Clinical Use
Clindamycin is recommended for the treatment of a widevariety of upper respiratory, skin, and tissue infections causedby susceptible bacteria. Its activity against streptococci,staphylococci, and pneumococci is indisputably high, and it isone of the most potent agents available against somenon–spore-forming anaerobic bacteria, the Bacteroides spp.in particular. An increasing number of reports of clindamycin-associated GI toxicity, which range in severity fromdiarrhea to an occasionally serious pseudomembranous colitis,have, however, caused some clinical experts to call for areappraisal of the role of this antibiotic in therapy.Clindamycin- (or lincomycin)-associated colitis may be particularlydangerous in elderly or debilitated patients and hascaused deaths in such individuals. The colitis, which is usuallyreversible when the drug is discontinued, is now believedto result from an overgrowth of a clindamycin-resistant strainof the anaerobic intestinal bacterium Clostridium difficile.229The intestinal lining is damaged by a glycoprotein endotoxinreleased by lysis of this organism.
The glycopeptide antibiotic vancomycin has been effectivein the treatment of clindamycin-induced pseudomembranouscolitis and in the control of the experimentally induced bacterial condition in animals. Clindamycin shouldbe reserved for staphylococcal tissue infections, such as cellulitisand osteomyelitis, in penicillin-allergic patients andfor severe anaerobic infections outside the central nervoussystem. Ordinarily, it should not be used to treat upper respiratorytract infections caused by bacteria sensitive to othersafer antibiotics or in prophylaxis.
Veterinary Drugs and Treatments
Clindamycin products are approved for use in dogs and cats. The labeled indications for dogs include wounds, abscesses and osteomyelitis caused by Staphylococcus aureus. Because clindamycin has excellent activity against most pathogenic anaerobic organisms, it is also used extensively for those infections. Clindamycin is used for a variety of protozoal infections, including toxoplasmosis. For further information, refer to the Dosage or Pharmacology sections.
Lager
-20°C

Clindamycin hydrochloride Upstream-Materialien And Downstream Produkte

Clindamycinhydrochlorid Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

21462-39-5, Clindamycin hydrochloride Verwandte Suche:

Send Inquriy